The financial regulator in the US has sent letters to 10 companies that it claims have improperly listed patents in the FDA’s ‘Orange Book’ in order to block generic rivals.
The Federal Trade Commission (FTC) is contesting the validity of more than 100 patents held by manufacturers of brand-name asthma inhalers, epinephrine autoinjectors, and other drug products, and has told the FDA that it disputes their “accuracy or relevance.”
